Summary

This article presents results from a randomized trial that prospectively compared the glycemic control achieved using basal insulin glargine, exenatide, and metformin therapy (BET) with basal insulin glargine, bolus insulin lispro, and metformin therapy (BBT) in subjects with type 2 diabetes mellitus (T2DM). The results support BET as an alternative to BBT in some patients with T2DM [Wolffenbuttel BHR et al. EASD 2013 (abstr 1); NCT00960661].